D. E. Shaw & Co. Inc. Buys 95,192 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

D. E. Shaw & Co. Inc. grew its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 402.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 118,851 shares of the company's stock after buying an additional 95,192 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.25% of Amphastar Pharmaceuticals worth $4,413,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Smartleaf Asset Management LLC lifted its position in shares of Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after purchasing an additional 493 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after purchasing an additional 871 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after purchasing an additional 348 shares during the last quarter. Huntington National Bank lifted its position in shares of Amphastar Pharmaceuticals by 36.9% during the 4th quarter. Huntington National Bank now owns 1,340 shares of the company's stock worth $50,000 after purchasing an additional 361 shares during the last quarter. Finally, TD Private Client Wealth LLC increased its stake in Amphastar Pharmaceuticals by 22.7% during the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock valued at $78,000 after acquiring an additional 388 shares during the period. Institutional investors and hedge funds own 65.09% of the company's stock.

Insider Activity

In other news, CFO William J. Peters sold 4,231 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This represents a 4.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 5,231 shares of company stock worth $142,752. Company insiders own 27.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on AMPH shares. JPMorgan Chase & Co. restated a "neutral" rating and set a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Wells Fargo & Company lowered their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Finally, Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $32.33.

Amphastar Pharmaceuticals Stock Performance

AMPH traded up $0.27 on Friday, hitting $24.47. 548,566 shares of the stock traded hands, compared to its average volume of 480,046. Amphastar Pharmaceuticals, Inc. has a 52 week low of $22.64 and a 52 week high of $53.96. The firm has a market capitalization of $1.16 billion, a PE ratio of 8.16, a P/E/G ratio of 2.19 and a beta of 0.78. The business has a fifty day moving average price of $25.20 and a two-hundred day moving average price of $33.05. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.